Signalisation JAK/STAT
Les inhibiteurs de la signalisation JAK/STAT sont des composés qui perturbent la voie des kinases Janus (JAK) et du transducteur et activateur de transcription (STAT), impliquée dans la signalisation des cytokines, la croissance cellulaire et la réponse immunitaire. Ces inhibiteurs sont des outils importants pour étudier la régulation de cette voie et son rôle dans diverses maladies, notamment les cancers, les troubles immunitaires et les affections inflammatoires. Les inhibiteurs JAK/STAT sont également en cours de développement en tant que thérapies ciblées pour ces maladies. Chez CymitQuimica, nous offrons une large sélection d'inhibiteurs de haute qualité de la signalisation JAK/STAT pour soutenir vos recherches en biologie moléculaire, oncologie et immunologie.
Sous-catégories appartenant à la catégorie "Signalisation JAK/STAT"
365 produits trouvés pour "Signalisation JAK/STAT"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK-IN-1
CAS :JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Formule :C20H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.44Pim-1 kinase inhibitor 5
CAS :Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-Formule :C22H13Cl2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :406.26PIM1-IN-1
CAS :PIM1-IN-1 inhibits PIM1/3 with IC50s: PIM1 (7 nM), PIM2 (5530 nM), PIM3 (70 nM); it has anti-cancer properties.Formule :C25H30N8O2Degré de pureté :98.59%Couleur et forme :SolidMasse moléculaire :474.56Ref: TM-T12474
10mgÀ demander1mL*10mM (DMSO)À demander1mg117,00€5mg281,00€25mg858,00€50mg1.341,00€100mg2.125,00€GNE-955
CAS :GNE-955 is a potent and orally active inhibitor of pan Pim kinase (Kis: 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively).Formule :C22H24N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :416.48JAK-IN-31
CAS :JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,Formule :C21H19N7O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :465.55QL-1200186
CAS :QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production followingFormule :C26H27N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :485.54JAK kinase-IN-1
CAS :JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Formule :C17H19F2N7OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.44JAK-IN-25
CAS :JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.Formule :C19H17N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :379.37STAT6-IN-3
CAS :STAT6-IN-3 (Compound 18a) serves as an inhibitor of STAT6 with an IC50 value of 44 nM, specifically targeting the Src Homology 2 (SH2) domain.Formule :C32H35IN3O7PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :731.51PIM-IN-2
CAS :PIM-IN-2 (Pim-2) is a potent inhibitor of Pim kinases, demonstrating an inhibition concentration half-maximal (IC50) value of 25 nM .Formule :C19H22N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :338.4NMS-P953
CAS :NMS-P953: JAK2 inhibitor, reduces tumor growth in SET-2 model, confirmed in vivo action, good pharmacokinetics and safety.Formule :C16H11ClF3N5OCouleur et forme :SolidMasse moléculaire :381.74JAK-IN-3
CAS :JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.Formule :C18H20N4O3Degré de pureté :98.04% - 98.19%Couleur et forme :SolidMasse moléculaire :340.38Ref: TM-T11704
1mg126,00€2mg178,00€5mg304,00€1mL*10mM (DMSO)334,00€10mg492,00€25mg982,00€50mg1.558,00€100mg2.538,00€200mg3.402,00€STAT6-IN-2
CAS :STAT6-IN-2(R)-84 is a STAT6 inhibitor that inhibits the secretion of eotaxin-3 and the tyrosine phosphorylation of STAT6.Formule :C28H31N5O2Degré de pureté :99.67%Couleur et forme :SolidMasse moléculaire :469.58HS94
CAS :HS94 (DAPK3 inhibitor HS94) is a selective and potent DAPK3 inhibitor with a Ki value of 126 nM for Pim kinase inhibition and can be used to study hypertension.
Formule :C15H15N5O2SDegré de pureté :95.04%Couleur et forme :SolidMasse moléculaire :329.38iBFAR2
CAS :iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.
Formule :C19H15F3N2O2Couleur et forme :SolidMasse moléculaire :360.33Tyk2-IN-3
CAS :Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).Formule :C25H24N6O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :520.63(3S,4R)-Tofacitinib
CAS :(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Formule :C23H22Cl2N4OCouleur et forme :SolidMasse moléculaire :441.35TYK2 ligand 2
CAS :TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.Formule :C24H20FN7O4Couleur et forme :SolidMasse moléculaire :489.458GDC-9918
CAS :GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.Formule :C20H18F2N6O5SCouleur et forme :SolidMasse moléculaire :492.46JAK3 covalent inhibitor-1
CAS :JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFormule :C22H17FN6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.47CEE321
CAS :CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.Formule :C18H16ClN5OCouleur et forme :SolidMasse moléculaire :353.806JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Formule :C26H36FN5O2Couleur et forme :SolidMasse moléculaire :469.59JAK1/TYK2-IN-4
CAS :JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].Formule :C17H23N7OCouleur et forme :SolidMasse moléculaire :341.41CP-352664
CAS :CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Formule :C18H18N4Couleur et forme :SolidMasse moléculaire :290.36Tyk2-IN-17
CAS :Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].Formule :C20H20F2N8OCouleur et forme :SolidMasse moléculaire :426.42Tyk2-IN-20
CAS :Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Formule :C24H25N7O2Couleur et forme :SolidMasse moléculaire :443.50JAK2-IN-11
CAS :JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formule :C31H31F3N8O4Couleur et forme :SolidMasse moléculaire :639.64SI-109
CAS :SI-109 is a potent inhibitor of STAT3 SH2 domain (Ki=9 nM),and with antitumor activity.Formule :C40H44F2N7O9PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :835.79PF-06263276
CAS :PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).Formule :C31H31FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :566.63JAK3-IN-7
CAS :JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormule :C17H20N6ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :324.38lirucitinib
CAS :Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468STAT3-IN-36
CAS :STAT3-IN-36 (compound 11g) is a tritarget inhibitor that selectively targets LRPPRC, STAT3, and CDK1, exhibiting potent anticancer activity. This compound binds to LRPPRC, STAT3, and CDK1, demonstrating more effective anticancer effects than those of TMF or Capecitabine. Additionally, STAT3-IN-36 exhibits an IC50 value of 1.8 μM in HGC27 cells.Formule :C30H24F2N2O9S2Couleur et forme :SolidMasse moléculaire :658.65AZ-3
CAS :AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Formule :C20H28FN7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :385.48Tyk2-IN-10
CAS :Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.Formule :C25H27N5O3Couleur et forme :SolidMasse moléculaire :445.51LNK01004
CAS :LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.Formule :C26H31N7O2Couleur et forme :SolidMasse moléculaire :473.57Milpecitinib
CAS :Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463Tyk2-IN-14
CAS :Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formule :C22H21N9O2Couleur et forme :SolidMasse moléculaire :443.46JAK3-IN-11
CAS :JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Formule :C23H23N5O2Couleur et forme :SolidMasse moléculaire :401.46JAK1-IN-9
CAS :JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.Formule :C16H13IN6Couleur et forme :SolidMasse moléculaire :416.2215(R)-Lipoxin A4
CAS :Lipid-derived lipoxins are produced at the site of vascular and mucosal inflammation where they down-regulate polymorphonuclear leukocyte recruitment andFormule :C20H32O5Couleur et forme :SolidMasse moléculaire :352.47Pim-1 kinase inhibitor 6
CAS :Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].Formule :C21H10BrCl2N3Couleur et forme :SolidMasse moléculaire :455.13Prohibitin ligand 1
Compound 22i, a prohibitin ligand, protects the heart at nanomolar levels by inducing STAT3 phosphorylation.Formule :C20H22N2OCouleur et forme :SolidMasse moléculaire :306.4WZ-2-033
CAS :WZ-2-033 is a potent STAT3 inhibitor. It inhibits proliferation, colony survival, migration, and invasion of MDA-MB-231, HCC70, and MDA-MB231-4175 cells, with IC50 values of 0.7, 1.3, and 1.3 μM respectively.Formule :C25H18F3N3O4SCouleur et forme :SolidMasse moléculaire :513.49STAT3-IN-8
CAS :"STAT3-IN-8 (compound H172) is a potent inhibitor of STAT3 with potential applications in cancer research [1]."Formule :C19H7F7N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :444.26GDC-0339
CAS :GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.Formule :C20H22F3N7OSCouleur et forme :SolidMasse moléculaire :465.5JAK2 JH2 binder-1
CAS :JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.Formule :C29H25N7O6SCouleur et forme :SolidMasse moléculaire :599.62STAT3-IN-35
CAS :STAT3-IN-35 is a STAT3 inhibitor that binds to the SH2 domain. This compound inhibits the phosphorylation of STAT3 and exhibits antiproliferative activity in triple-negative breast cancer (TNBC) cell lines. Additionally, STAT3-IN-35 has demonstrated toxicity and potent antitumor activity in TNBC xenograft models.Formule :C21H23NO4Couleur et forme :SolidMasse moléculaire :353.41Ofirnoflastum
CAS :Ofirnoflastum (Ofirnoflast) is an inhibitor of the serine/threonine-protein kinase Nek7, known for its anti-inflammatory properties.Formule :C23H19F4N7O2Couleur et forme :SolidMasse moléculaire :501.44Ten01
Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.Formule :C18H20F6N4OCouleur et forme :SolidMasse moléculaire :422.37STAT3-IN-7
CAS :STAT3-IN-7, an orally active aryl sulfonamido azetidine compound, serves as a STAT3 inhibitor with anticancer activities.Formule :C30H26F5N5O4SCouleur et forme :SolidMasse moléculaire :647.62Londamocitinib
CAS :Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.Formule :C28H31F2N7O4SDegré de pureté :98.64% - 99.56%Couleur et forme :SolidMasse moléculaire :599.65Ref: TM-T11706
1mg170,00€5mg416,00€1mL*10mM (DMSO)537,00€10mg567,00€25mg858,00€50mg1.108,00€100mg1.485,00€YLIU-4-105-1
CAS :YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Formule :C32H34F3N7O2Couleur et forme :SolidMasse moléculaire :605.65Cenacitinib
CAS :Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formule :C19H19F2N7O3Couleur et forme :SolidMasse moléculaire :431.40JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Couleur et forme :SolidTyk2-IN-15
CAS :Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].Formule :C21H25F2N7OCouleur et forme :SolidMasse moléculaire :429.47JDTic
CAS :JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formule :C28H39N3O3Couleur et forme :SolidMasse moléculaire :465.63(3R,4S)-Tofacitinib
CAS :(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37JAK2-IN-9
CAS :Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.
Formule :C20H24N6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :412.51JAK-IN-34
CAS :JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,
Formule :C27H26N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :450.53DPP
CAS :DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating
Formule :C36H40Cl2N2O10PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :926.7STAT3-IN-18
CAS :STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and
Formule :C18H24Cl2N2O6PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :630.38JAK-IN-27
CAS :JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM
Formule :C20H21F2N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :413.42JAK1-IN-11
CAS :JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.
Formule :C26H36N6O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.67JAK1-IN-10
CAS :JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
Formule :C15H17N7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :295.34
